← stocks-llm Find companies like PRCT →

PROCEPT BIOROBOTICS CORP (PRCT)

Health Care · Surgical robotics for urology · NASDAQ

Surgical robotics company pioneering image-guided waterjet ablation systems (AquaBeam/HYDROS) for minimally invasive treatment of benign prostate enlargement.

What PROCEPT BIOROBOTICS CORP does

PROCEPT BioRobotics develops and sells the AquaBeam Robotic System and HYDROS Robotic System, advanced image-guided surgical robotic platforms that deliver proprietary Aquablation therapy—a heat-free waterjet ablation technique—for minimally invasive treatment of benign prostatic hyperplasia (BPH). The company's robotic systems employ single-use disposable handpieces to enable consistent, reproducible surgical outcomes in urology. As of December 31, 2025, PROCEPT had an install base of 912 systems globally, including 718 in the United States.

Themes: ["surgical robotics","minimally invasive urology","benign prostatic hyperplasia (BPH) treatment","robotic-assisted surgery"]

Fundamentals

Ask why PRCT looks like this →

Key risks (from latest filing)

["Unprofitable with negative net margin of -31.82% and significant accumulated deficit; highly dependent on commercialization success and market adoption of Aquablation therapy","Severe stock price decline of -66.22% over one year indicates investor concern about commercial trajectory and competitive positioning","Regulatory and reimbursement risks: continued FDA approvals and insurance coverage required for sustained revenue growth in a competitive surgical robotics market"]

See PRCT's biggest risks from its latest 10-Q →

Competitors & peers

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.